{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:58:17Z","timestamp":1793228297413,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guideline-recommended hyperkalaemia management includes dietary potassium (K+) restriction, bicarbonate correction, diuretics and K+ binders with dose reduction of renin\u2013angiotensin\u2013aldosterone system inhibitors as a last resort. The extent to which these recommendations are implemented is uncertain, as real-world data on hyperkalaemia management are limited. The Tracking Treatment Pathways in Adult Patients with Hyperkalemia (TRACK) study is a multinational, prospective, longitudinal study that is being conducted to address this knowledge gap. We report the design and baseline cohort characteristics of this real-world study of hyperkalaemia management decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study enrolled participants within 21\u00a0days of an episode of hyperkalaemia in four European countries (UK, Spain, Germany, Italy) and the USA. During the 12-month follow up, data collected will include participant and healthcare provider characteristics (specialty and practice setting), hyperkalaemia treatment objectives and strategies, rationale for management decisions and indicators of response and patient-reported perceptions of their hyperkalaemia treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The enrolled cohort includes 1330 participants, mean age 68\u00a0years, of whom 31% were women. At baseline, 6% reported heart failure, 55% chronic kidney disease, 29% both and 9% neither. Most participants (57%) were taking an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker or angiotensin receptor\/neprilysin inhibitor at baseline. Mineralocorticoid receptor antagonist use was lower (14%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prospective TRACK study will shed light on practitioners\u2019 hyperkalaemia management decision-making and assess the impact of their decisions on hyperkalaemia recurrence. Understanding practitioners\u2019 underlying thought processes will facilitate efforts to improve hyperkalaemia management.<\/jats:p>\n                    <jats:p>ClinicalTrials.gov: NCT05408039<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfae295","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T23:15:49Z","timestamp":1727565349000},"source":"Crossref","is-referenced-by-count":3,"title":["Design and cohort characteristics of TRACK, a prospective study of hyperkalaemia management decision-making"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3413-7836","authenticated-orcid":false,"given":"Judith","family":"Hsia","sequence":"first","affiliation":[{"name":"CPC Clinical Research, University of Colorado , Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Shivappa","sequence":"additional","affiliation":[{"name":"AstraZeneca , Wilmington, DE ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameet","family":"Bakhai","sequence":"additional","affiliation":[{"name":"Royal Free NHS Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bover","sequence":"additional","affiliation":[{"name":"Hospital Germans Trias i Pujol , Badalona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott & White Research Institute, Dallas, TX, and University of Mississippi , Jackson, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-022X","authenticated-orcid":false,"given":"Pietro Manuel","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Verona , Verona,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Fried","sequence":"additional","affiliation":[{"name":"Pittsburgh Healthcare System , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus P","family":"Schneider","sequence":"additional","affiliation":[{"name":"University of Erlangen-N\u00fcrnberg , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[{"name":"University of Manitoba , Winnipeg , MB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang C","family":"Winkelmayer","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Bishop","sequence":"additional","affiliation":[{"name":"AstraZeneca , Gaithersburg, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hungta","family":"Chen","sequence":"additional","affiliation":[{"name":"AstraZeneca , Wilmington, DE ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Karin","family":"Sundin","sequence":"additional","affiliation":[{"name":"AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P","family":"Bonaca","sequence":"additional","affiliation":[{"name":"CPC Clinical Research, University of Colorado , Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"2024102509312147400_bib1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ckj\/sfab243","article-title":"How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies","volume":"15","author":"Humphrey","year":"2022","journal-title":"Clin Kidney J"},{"key":"2024102509312147400_bib2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1053\/j.ajkd.2021.07.008","article-title":"Population epidemiology of hyperkalemia: cardiac and kidney long-term health outcomes","volume":"79","author":"Mclean","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2024102509312147400_bib3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ekir.2017.11.003","article-title":"The cost of hyperkalemia in the United States","volume":"3","author":"Betts","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2024102509312147400_bib4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12882-020-01942-2","article-title":"The burden of hyperkalemia in Germany\u2014a real world evidence study assessing the treatment and costs of hyperkalemia","volume":"21","author":"Haas","year":"2020","journal-title":"BMC Nephrol"},{"key":"2024102509312147400_bib5","doi-asserted-by":"publisher","first-page":"e14326","DOI":"10.1111\/ijcp.14326","article-title":"Health-related quality of life and lifestyle changes in patients with chronic kidney disease and hyperkalaemia: real-world data from the US, five European countries and China","volume":"75","author":"Grandy","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2024102509312147400_bib6","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s12325-024-02835-8","article-title":"Hyperkalemia recurrence following medical nutrition therapy in patients with stage 3-4 chronic kidney disease: the REVOLUTIONIZE I real-world study","volume":"41","author":"Rowan","year":"2024","journal-title":"Adv Ther"},{"key":"2024102509312147400_bib7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/ejhf.2612","article-title":"An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum","volume":"24","author":"Burton","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4 Suppl","key":"2024102509312147400_bib8","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2024102509312147400_bib9","article-title":"Clinical practice guidelines. Treatment of acute hyperkalaemia in adults.","author":"Alfonzo"},{"key":"2024102509312147400_bib10","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2024102509312147400_bib11","article-title":"FACIT-TS-G. Functional Assessment of Chronic Illness Therapy \u2013 Treatment Satisfaction \u2013 General","author":"FACIT Group"},{"key":"2024102509312147400_bib12","article-title":"Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blockers (ARBs). ACE inhibitors and ARBs, a cornerstone in the prevention and treatment of cardiovascular disease","author":"Asenjo"},{"key":"2024102509312147400_bib13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2215\/CJN.00950121","article-title":"Recurrent hyperkalaemia in renin-angiotensin-aldosterone system inhibitor (RAASi) treatment: stuck between a rock and a hard place","volume":"16","author":"Bola\u00f1os","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024102509312147400_bib14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s12325-021-02017-w","article-title":"Real-world management of hyperkalaemia in the emergency department: an electronic medical record analysis","volume":"39","author":"Davis","year":"2022","journal-title":"Adv Ther"},{"key":"2024102509312147400_bib15","doi-asserted-by":"publisher","first-page":"rmae001","DOI":"10.1093\/jphsr\/rmae001","article-title":"Patient's perception of medication and non-adherence to chronic disease treatments. A population-based study in Brazil","volume":"15","author":"Da Silva Menolli","year":"2024","journal-title":"J Pharm Health Serv Res"},{"key":"2024102509312147400_bib16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/00325481.2019.1706920","article-title":"Real-world management of hyperkalemia with patiromer among United States veterans","volume":"132","author":"Kovesdy","year":"2020","journal-title":"Postgrad Med"},{"key":"2024102509312147400_bib17","doi-asserted-by":"publisher","first-page":"e0226844","DOI":"10.1371\/journal.pone.0226844","article-title":"Hyperkalemia treatment modalities: a descriptive observational study focused on medication and healthcare resource utilization","volume":"15","author":"Desai","year":"2020","journal-title":"PLoS One"},{"key":"2024102509312147400_bib18","doi-asserted-by":"publisher","first-page":"sfae083","DOI":"10.1093\/ckj\/sfae083","article-title":"Maintained renin\u2013angiotensin\u2013aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study","volume":"17","author":"Rastogi","year":"2024","journal-title":"Clin Kidney J"},{"key":"2024102509312147400_bib19","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019\u20132020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2024102509312147400_bib20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pcad.2024.01.008","article-title":"Bridging gaps and optimizing implementation of guideline-directed medical therapy for heart failure","volume":"82","author":"Shahid","year":"2024","journal-title":"Prog Cardiovasc Dis"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae295\/59463859\/sfae295.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/10\/sfae295\/60080727\/sfae295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/10\/sfae295\/60080727\/sfae295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T05:31:32Z","timestamp":1729834292000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae295\/7797276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae295","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,9,30]]},"article-number":"sfae295"}}